Chemists have figured out a new, more efficient way to create carbon-based fuels from carbon dioxide (CO2). In chemical reactions performed in the lab, a Caltech team has identified a new additive that helps selectively convert CO2 into fuels containing multiple carbon atoms—a step toward ultimately making renewable liquid fuels that are not derived from coal or oil.

"The results were quite shocking," says Jonas Peters, Bren Professor of Chemistry at Caltech and director of the Resnick Sustainability Institute, who jointly led the research in collaboration with Theodor Agapie, professor of chemistry at Caltech. "Usually, in these types of reactions with CO2, you see a lot of by-products like methane and hydrogen. In this case, the reaction was highly selective for the more desirable fuels that contain multiple carbons—such as ethylene, ethanol, and propanol. We saw an 80 percent conversion to these multi-carbon fuel products, with only 20 percent or so going into hydrogen and methane."

Read more ...

Seasonal and diurnal rhythms determine the life cycle of many animal species. In equids this is not only true for wild species such as the Przewalski but season-dependent metabolic changes also exist in domesticated horses. Horses can reduce their metabolic activity during the cold season and thus reduce heat loss. The effects of such seasonal changes on pregnancy and foetal development, however, have not been investigated so far. Researchers from Vetmeduni Vienna could now demonstrate that foals born in winter are smaller than herd mates born later in the year.

Read more ...

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have published a study in Nature Communications shedding new light on how K-80003 (TX803), an anti-cancer agent discovered at the Institute, prevents activation of the PI3K pathway, resulting in inhibition of cancer cell growth. Because the PI3K pathway is common to many cancers, K-80003 could have broad therapeutic applications. Tarrex Biopharma, Inc. has licensed the compound and announced they will soon begin Phase 1 clinical trials at the Dana Farber Cancer Center for patients with colorectal cancer.

Read more ...

More Articles ...

Subcategories